Cesar Rodriguez, MD

Articles by Cesar Rodriguez, MD

Induction Therapy in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

DETERMINATION, GRIFFIN, and MASTER Studies

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Induction Regimen Options in Transplant-Eligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Cesar Rodriguez, MD

Articles by Cesar Rodriguez, MD

Induction Therapy in Transplant-Ineligible NDMM

Role of Transplant and Induction Therapies in NDMM

DETERMINATION, GRIFFIN, and MASTER Studies

Induction Regimen Options in Transplant-Eligible NDMM

Trending on CancerNetwork

Alcohol-Attributable Cancer Mortality Has Doubled in the US Since 1990

How Will Ropeginterferon Alfa’s Approval Impact Essential Thrombocythemia?

FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC

Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer